{"entity":{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","aka":[],"tldr":"Chief investigator of monarchE, the trial that added abemaciclib to adjuvant endocrine therapy for high-risk early breast cancer.","summary":"Stephen Johnston led monarchE, which showed two years of abemaciclib with endocrine therapy cuts recurrence in node-positive, high-risk HR-positive early breast cancer, the first adjuvant CDK4/6 inhibitor approval. His earlier work defined mechanisms of endocrine resistance and the fulvestrant dose used today. He continues to lead adjuvant and oral SERD trials from the Royal Marsden.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnston%20SRD%5BAuthor%5D%20abemaciclib"}],"tags":["breast","trialist"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cdk46-inhibitor","endocrine-therapy"],"targets":["cdk4-6","estrogen-receptor"],"drugs":["abemaciclib"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["monarche"],"people":[],"bottlenecks":[],"keyPapers":["paper-monarche-jco-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Cancer Medicine, Royal Marsden and Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["HR-positive breast cancer","Adjuvant CDK4/6 inhibition","Endocrine resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnston%20SRD%5BAuthor%5D%20abemaciclib"}],"papers":[{"title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","journal":"JCO","year":2020,"doi":"10.1200/JCO.20.02514"},{"title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","journal":"Lancet Oncology","year":2023},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}],"orcid":"0000-0002-9072-2749"},"route":"/people/stephen-johnston/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"}],"institution":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"trial":[{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/"}],"paper":[{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/"}]}}